Publication

Ganciclovir Therapeutic Drug Monitoring: A Case Series

Märtson, A-G., Touw, D., Damman, K., Bakker, M., Lansink-Hartgring, A. O., van der Werf, T., Knoester, M. & Alffenaar, J-W. C., 1-Apr-2019, In : Therapeutic Drug Monitoring. 41, 2, p. 107-110 4 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Märtson, A-G., Touw, D., Damman, K., Bakker, M., Lansink-Hartgring, A. O., van der Werf, T., ... Alffenaar, J-W. C. (2019). Ganciclovir Therapeutic Drug Monitoring: A Case Series. Therapeutic Drug Monitoring, 41(2), 107-110. https://doi.org/10.1097/FTD.0000000000000598

Author

Märtson, Anne-Grete ; Touw, Daan ; Damman, Kevin ; Bakker, Martijn ; Lansink-Hartgring, Annemieke Oude ; van der Werf, Tjip ; Knoester, Marjolein ; Alffenaar, Jan-Willem C. / Ganciclovir Therapeutic Drug Monitoring : A Case Series. In: Therapeutic Drug Monitoring. 2019 ; Vol. 41, No. 2. pp. 107-110.

Harvard

Märtson, A-G, Touw, D, Damman, K, Bakker, M, Lansink-Hartgring, AO, van der Werf, T, Knoester, M & Alffenaar, J-WC 2019, 'Ganciclovir Therapeutic Drug Monitoring: A Case Series', Therapeutic Drug Monitoring, vol. 41, no. 2, pp. 107-110. https://doi.org/10.1097/FTD.0000000000000598

Standard

Ganciclovir Therapeutic Drug Monitoring : A Case Series. / Märtson, Anne-Grete; Touw, Daan; Damman, Kevin; Bakker, Martijn; Lansink-Hartgring, Annemieke Oude; van der Werf, Tjip; Knoester, Marjolein; Alffenaar, Jan-Willem C.

In: Therapeutic Drug Monitoring, Vol. 41, No. 2, 01.04.2019, p. 107-110.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Märtson A-G, Touw D, Damman K, Bakker M, Lansink-Hartgring AO, van der Werf T et al. Ganciclovir Therapeutic Drug Monitoring: A Case Series. Therapeutic Drug Monitoring. 2019 Apr 1;41(2):107-110. https://doi.org/10.1097/FTD.0000000000000598


BibTeX

@article{189330cd608d450a854bf17c2c2979b8,
title = "Ganciclovir Therapeutic Drug Monitoring: A Case Series",
abstract = "This paper presents three cases of immunocompromised patients for whom therapeutic drug monitoring (TDM) of ganciclovir in combination with cytomegalovirus (CMV) viral load measurement was used to guide treatment. The first patient is diagnosed with Thymoma A, the second is a heart transplant recipient and the third is an HIV positive patient. These patients were all diagnosed with CMV and treated with ganciclovir. Our case studies illustrate how TDM guided dosing can be helpful in the management of these complex cases.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.",
author = "Anne-Grete M{\"a}rtson and Daan Touw and Kevin Damman and Martijn Bakker and Lansink-Hartgring, {Annemieke Oude} and {van der Werf}, Tjip and Marjolein Knoester and Alffenaar, {Jan-Willem C}",
year = "2019",
month = "4",
day = "1",
doi = "10.1097/FTD.0000000000000598",
language = "English",
volume = "41",
pages = "107--110",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "2",

}

RIS

TY - JOUR

T1 - Ganciclovir Therapeutic Drug Monitoring

T2 - A Case Series

AU - Märtson, Anne-Grete

AU - Touw, Daan

AU - Damman, Kevin

AU - Bakker, Martijn

AU - Lansink-Hartgring, Annemieke Oude

AU - van der Werf, Tjip

AU - Knoester, Marjolein

AU - Alffenaar, Jan-Willem C

PY - 2019/4/1

Y1 - 2019/4/1

N2 - This paper presents three cases of immunocompromised patients for whom therapeutic drug monitoring (TDM) of ganciclovir in combination with cytomegalovirus (CMV) viral load measurement was used to guide treatment. The first patient is diagnosed with Thymoma A, the second is a heart transplant recipient and the third is an HIV positive patient. These patients were all diagnosed with CMV and treated with ganciclovir. Our case studies illustrate how TDM guided dosing can be helpful in the management of these complex cases.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

AB - This paper presents three cases of immunocompromised patients for whom therapeutic drug monitoring (TDM) of ganciclovir in combination with cytomegalovirus (CMV) viral load measurement was used to guide treatment. The first patient is diagnosed with Thymoma A, the second is a heart transplant recipient and the third is an HIV positive patient. These patients were all diagnosed with CMV and treated with ganciclovir. Our case studies illustrate how TDM guided dosing can be helpful in the management of these complex cases.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

U2 - 10.1097/FTD.0000000000000598

DO - 10.1097/FTD.0000000000000598

M3 - Article

VL - 41

SP - 107

EP - 110

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 2

ER -

ID: 75365486